Evidence map›Paper›PMID 39605463›Full record

ArticlebioRxiv : the preprint server for biology2024

Programmable protein degraders enable selective knockdown of pathogenic β-catenin subpopulations

Tianzheng Ye, Azmain Alamgir, Cara M Robertus, Darianna Colina, Connor Monticello, Thomas Connor Donahue, Lauren Hong, Sophia Vincoff, Shrey Goel, Peter Fekkes and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Tianzheng YeRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853 USA.
Azmain AlamgirRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853 USA.
Cara M RobertusNancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York 14853 USA.
Darianna ColinaBiochemistry, Molecular and Cell Biology, Cornell University, Ithaca, NY 14853 USA.
Connor MonticelloNancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York 14853 USA.
Thomas Connor DonahueRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853 USA.
Lauren HongDepartment of Biomedical Engineering, Duke University, Durham, NC 27708 USA.
Sophia VincoffDepartment of Biomedical Engineering, Duke University, Durham, NC 27708 USA.
Shrey GoelDepartment of Biomedical Engineering, Duke University, Durham, NC 27708 USA.
Peter FekkesUbiquiTx, 750 Main Street, Cambridge, MA 02139 USA.
Luis Miguel CamargoUbiquiTx, 750 Main Street, Cambridge, MA 02139 USA.
Kieu LamGenevant Sciences Corporation, 887 Great Northern Way, Vancouver, BC, V5T 4T5 Canada.
James HeyesGenevant Sciences Corporation, 887 Great Northern Way, Vancouver, BC, V5T 4T5 Canada.
David PutnamRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853 USA.
Christopher A AlabiRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853 USA.
Pranam ChatterjeeDepartment of Biomedical Engineering, Duke University, Durham, NC 27708 USA.
Matthew P DeLisaRobert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853 USA.ORCID 0000-0003-3226-1566

Funding

Training future leaders at the chemistry-biology interfaceT32GM138826 · NIGMS · CORNELL UNIVERSITY · PI Jeremy Baskin · 2021 to 2026
$2.6M
Programmable peptide-guided protein degradationR21CA278468 · NCI · DUKE UNIVERSITY · PI CHATTERJEE, PRANAM · 2023 to 2023
$388k
Computational design and evaluation of peptide-guided protein degradersR41GM153081 · NIGMS · UBIQUITX, INC. · PI CAMARGO, LUIZ MIGUEL QUINN · 2024 to 2024
$313k
NCI NIH HHS R21 CA278468NIGMS NIH HHS R41 GM153081NIGMS NIH HHS T32 GM138826
6 · The paper itself

Abstract

Aberrant activation of Wnt signaling results in unregulated accumulation of cytosolic β-catenin, which subsequently enters the nucleus and promotes transcription of genes that contribute to cellular proliferation and malignancy. Here, we sought to eliminate pathogenic β-catenin from the cytosol using designer ubiquibodies (uAbs), chimeric proteins composed of an E3 ubiquitin ligase and a target-binding domain that redirect intracellular proteins to the proteasome for degradation. To accelerate uAb development, we leveraged a protein language model (pLM)-driven algorithm called SaLT&PepPr to computationally design "guide" peptides with affinity for β-catenin, which were subsequently fused to the catalytic domain of a human E3 called C-terminus of Hsp70-interacting protein (CHIP). Expression of the resulting peptide-guided uAbs in colorectal cancer cells led to the identification of several designs that significantly reduced the abnormally stable pool of free β-catenin in the cytosol and nucleus while preserving the normal membrane-associated subpopulation. This selective knockdown of pathogenic β-catenin suppressed Wnt/β-catenin signaling and impaired tumor cell survival and proliferation. Furthermore, one of the best degraders selectively decreased cytosolic but not membrane-associated β-catenin levels in livers of BALB/c mice following delivery as a lipid nanoparticle (LNP)-encapsulated mRNA. Collectively, these findings reveal the unique ability of uAbs to selectively eradicate abnormal proteins

Indexed as

biodegradersbioPROTACsE3 ubiquitin ligasemachine learningnon-antibody scaffoldspost-translational modificationprotein language modelsproximity-induced proteome editingtargeted protein degradationubiquitinationWnt/β-catenin signaling

Identifiers

PMID39605463
PMCPMC11601283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.